Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.
about
Cost impact of a non-invasive, portable device for patient self-administration of chronic migraine in a UK National Health Service settingTreatment of Chronic Migraine with OnabotulinumtoxinA: Mode of Action, Efficacy and SafetyHeadache management: pharmacological approachesChronic migraine headache prevention with noninvasive vagus nerve stimulation: The EVENT study.Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centersOnabotulinumtoxinA treatment for chronic migraine: experience in 52 patients treated with the PREEMPT paradigmOnabotulinumtoxinA for chronic migraine: a critical appraisal.Resolution of chronic migraine headaches with intrathecal ziconotide: a case report.Does analgesic overuse matter? Response to OnabotulinumtoxinA in patients with chronic migraine with or without medication overuseUse of botulinum toxin injections to treat peripheral stimulator induced facial muscle twitching: a case report.OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study.Increased efficacy of regularly repeated cycles with OnabotulinumtoxinA in MOH patients beyond the first year of treatment.Onabotulinumtoxin-A treatment in Greek patients with chronic migraineOnabotulinumtoxinA effectiveness on chronic migraine, negative emotional states and sleep quality: a single-center prospective cohort study.Botulinum toxin in the management of chronic migraine: clinical evidence and experience.OnabotulinumtoxinA injections in chronic migraine, targeted to sites of pericranial myofascial pain: an observational, open label, real-life cohort study.Utilization and safety of onabotulinumtoxinA for the prophylactic treatment of chronic migraine from an observational study in Europe.Chronic migraine treatment: from OnabotulinumtoxinA onwards.Chronic migraine: risk factors, mechanisms and treatment.Chronic Migraine: An Update on Physiology, Imaging, and the Mechanism of Action of Two Available Pharmacologic Therapies.Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline dataThe use of onabotulinum toxin A (Botox(®)) in the treatment of chronic migraine at the Parma Headache Centre: a prospective observational study.Prolonged Effect of OnabotulinumtoxinA on Chronic Migraine in 87 Koreans.Onabotulinum toxin A in the treatment of chronic migraine: patient selection and special considerations.OnabotulinumtoxinA in the treatment of patients with chronic migraine: clinical evidence and experience.Stopping Onabotulinum Treatment after the First Two Cycles Might Not Be Justified: Results of a Real-life Monocentric Prospective Study in Chronic Migraine.Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy.Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life.Effects of onabotulinumtoxinA treatment on efficacy, depression, anxiety, and disability in Turkish patients with chronic migraine.OnabotulinumtoxinA in chronic migraine: predictors of response. A prospective multicentre descriptive study.Long-term treatment of chronic migraine with OnabotulinumtoxinA: efficacy, quality of life and tolerability in a real-life setting.The Diagnosis and Management of Chronic Migraine in Primary Care.OnabotulinumtoxinA: A Review in the Prevention of Chronic Migraine.
P2860
Q26779553-4A5351E3-BF3B-4CAD-BE1A-CCA4371DE613Q26801753-93AE911F-4BDC-4751-83C5-0FA6413EAD0BQ27316751-C4AA4C96-220E-46AE-9A01-EDFF6A18EAB8Q27347591-FD84CFB1-975F-4559-ABA8-3E5E70F3639EQ31148427-C94F8196-29D0-4A6B-9CEF-DAF04EF65071Q33860731-E3082EEF-B92E-4AA2-8390-DA762973D9D0Q35435213-40D317FE-876B-4BCC-9153-C1F5E8385FDBQ35822040-09E52BE9-92A1-4E1E-A9C7-FF3E919B70B3Q36068584-7B7979F4-D3EA-4477-9013-6158862183E8Q36234332-DF61BA95-D884-4AEA-BA84-F5EA0B4EEEBBQ36249265-5576D82C-6A0C-4AEC-9668-5E721DED729BQ36415380-8FB5FF92-FC4A-4165-BE67-92A997534841Q36869674-5513F887-EF74-47AB-AF61-205BE66FB0C2Q37263045-99A10A80-6724-433E-B65C-C675DCB8ED57Q37650532-C868924E-9D8D-4CD6-83CC-22380CE96ABEQ37722781-4DE94C8C-A97B-4C9A-9E8F-B52AF79F6466Q38373498-4C7686BB-6FA0-48BA-A68B-CE1377AC84BEQ38652334-5897B035-2C69-44CE-90FB-5CF443A3658FQ38866988-CE2BAA4E-299A-4D97-82BD-CD83992712E7Q38889450-829941AB-F28B-432C-8AF0-74E36A534C71Q39026796-E2F77DE5-0B67-42D4-9085-DEA7CD110E10Q39150092-88A48BE9-FC8F-416A-99F1-7C5170396725Q39860994-C044BCC3-3CAE-41B8-BC28-991B16312BF2Q42329988-4FC7D389-BEE4-4DDE-8C88-711417FFC0B3Q42370565-67B32A31-C8B1-42D3-B57A-A368674D81B0Q47105597-2F98D12A-DB58-420F-B6AC-09B34E436F69Q47114851-D9710D76-870D-4B07-931E-7FE16B23C3F0Q47133621-7FEEF6F6-ABC2-4A2A-8BC8-E9040B5A0925Q47244918-445F58F1-56C7-4794-9B7F-C7181065C101Q47410678-A59A37C6-C6A7-417F-88CD-139B39D149E7Q47420416-8D23881B-803C-44A9-BCAB-12458C3D1EDCQ47785285-613158A8-F47E-4428-A56E-066667067FEFQ47828538-17BEE069-B7BC-4089-A7B8-84974C25F1ECQ52658935-BA46AE65-2D09-4DBC-80E4-AB208BE769B4
P2860
Prospective analysis of the use of OnabotulinumtoxinA (BOTOX) in the treatment of chronic migraine; real-life data in 254 patients from Hull, U.K.
description
2014 nî lūn-bûn
@nan
2014 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Prospective analysis of the us ...... n 254 patients from Hull, U.K.
@ast
Prospective analysis of the us ...... n 254 patients from Hull, U.K.
@en
type
label
Prospective analysis of the us ...... n 254 patients from Hull, U.K.
@ast
Prospective analysis of the us ...... n 254 patients from Hull, U.K.
@en
prefLabel
Prospective analysis of the us ...... n 254 patients from Hull, U.K.
@ast
Prospective analysis of the us ...... n 254 patients from Hull, U.K.
@en
P2093
P2860
P356
P1476
Prospective analysis of the us ...... n 254 patients from Hull, U.K.
@en
P2093
Fayyaz Ahmed
Hassan W Zafar
Victoria Quarshie
P2860
P2888
P356
10.1186/1129-2377-15-54
P50
P577
2014-09-01T00:00:00Z
P5875
P6179
1019795921